Increasing Rates of Diagnosis, Substantial Co-Occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis, and Colitis Based on 10-Year Data Across a Multicenter Consortium.
Adolescent
Adult
Anti-Inflammatory Agents
/ therapeutic use
Child
Child, Preschool
Colitis
/ diagnosis
Comorbidity
/ trends
Enteritis
/ diagnosis
Eosinophilia
/ diagnosis
Eosinophils
/ pathology
Female
Follow-Up Studies
Forecasting
Gastritis
/ diagnosis
Gastroenteritis
/ diagnosis
Gastrointestinal Agents
/ therapeutic use
Humans
Incidence
Infant
Intestinal Mucosa
/ pathology
Male
Middle Aged
Retrospective Studies
United States
/ epidemiology
Young Adult
Journal
The American journal of gastroenterology
ISSN: 1572-0241
Titre abrégé: Am J Gastroenterol
Pays: United States
ID NLM: 0421030
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
pubmed:
23
4
2019
medline:
28
2
2020
entrez:
23
4
2019
Statut:
ppublish
Résumé
The literature related to eosinophilic gastritis (EG), gastroenteritis (EGE), and colitis (EC) is limited. We aimed to characterize rates of diagnosis, clinical features, and initial treatments for patients with EG, EGE, and EC. In this retrospective study, data were collected from 6 centers in the Consortium of Eosinophilic Gastrointestinal Researchers from 2005 to 2016. We analyzed demographics, time trends in diagnosis, medical history, presenting symptoms, disease overlap, and initial treatment patterns/responses. Of 373 subjects (317 children and 56 adults), 38% had EG, 33% EGE, and 29% EC. Rates of diagnosis of all diseases increased over time. There was no male predominance, and the majority of subjects had atopy. Presenting symptoms were similar between diseases with nausea/vomiting and abdominal pain, the most common. One hundred fifty-four subjects (41%) had eosinophilic inflammation outside of their primary disease location with the esophagus the second most common gastrointestinal (GI) segment involved. Multisite inflammation was more common in children than in adults (68% vs 37%; P < 0.001). Initial treatment patterns varied highly between centers. One hundred-nine subjects (29%) had follow-up within 6 months, and the majority had clinical, endoscopic, and histologic improvements. In this cohort, EG, EGE, and EC were diagnosed more frequently over time, and inflammation of GI segments outside the primary disease site co-occurrence of atopy was common with a lack of male predominance. Symptoms were similar between diseases, and initial treatment strategies were highly variable. Future investigation should assess the cause of the increased prevalence of eosinophilic GI disorders and prospectively assess outcomes to establish treatment algorithms.
Identifiants
pubmed: 31008735
doi: 10.14309/ajg.0000000000000228
pmc: PMC6554065
mid: NIHMS1523540
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Gastrointestinal Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
984-994Subventions
Organisme : NIDDK NIH HHS
ID : K23 DK109263
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK078392
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32 DK007634
Pays : United States
Organisme : NIAID NIH HHS
ID : U54 AI117804
Pays : United States
Références
Gut Liver. 2018 May 15;12(3):288-296
pubmed: 29212311
Clin Gastroenterol Hepatol. 2011 Nov;9(11):950-956.e1
pubmed: 21806952
Transl Sci Rare Dis. 2017 Dec 18;2(3-4):141-155
pubmed: 29333363
Clin Gastroenterol Hepatol. 2010 Aug;8(8):669-75; quiz e88
pubmed: 20451664
Gastroenterol Clin North Am. 2014 Jun;43(2):317-27
pubmed: 24813518
Pediatr Gastroenterol Hepatol Nutr. 2015 Dec;18(4):253-60
pubmed: 26770900
J Allergy Clin Immunol. 2014 Nov;134(5):1114-24
pubmed: 25234644
Gastroenterol Res Pract. 2011;2011:857508
pubmed: 21837236
Med J Malaysia. 2015 Aug;70(4):232-7
pubmed: 26358020
J Pediatr. 2002 Oct;141(4):576-81
pubmed: 12378201
J Pediatr Gastroenterol Nutr. 2018 May;66(5):760-766
pubmed: 29095349
J Allergy Clin Immunol. 2011 Dec;128(6):1349-1350.e5
pubmed: 22019091
World J Gastroenterol. 2017 May 21;23(19):3556-3564
pubmed: 28596692
J Gastroenterol. 2013 Mar;48(3):333-9
pubmed: 22847555
Am J Gastroenterol. 2013 May;108(5):679-92; quiz 693
pubmed: 23567357
J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):36-42
pubmed: 25988554
J Pediatr Gastroenterol Nutr. 2011 Mar;52(3):300-6
pubmed: 21057327
Clin Res Hepatol Gastroenterol. 2018 Oct;42(5):483-493
pubmed: 29615329
United European Gastroenterol J. 2017 Apr;5(3):335-358
pubmed: 28507746
Aliment Pharmacol Ther. 2016 Jan;43(1):3-15
pubmed: 26510832
Scand J Gastroenterol. 2001 Dec;36(12):1358-60
pubmed: 11761030
Am J Gastroenterol. 2014 Aug;109(8):1277-85
pubmed: 24957155
Dig Liver Dis. 2015 Mar;47(3):197-201
pubmed: 25547198
Gut. 1990 Jan;31(1):54-8
pubmed: 2318432
Clin Gastroenterol Hepatol. 2017 Nov;15(11):1733-1741
pubmed: 28603057
J Pediatr Gastroenterol Nutr. 2015 Jul;61(1):56-64
pubmed: 25699593
Gastroenterol Clin North Am. 2014 Jun;43(2):257-68
pubmed: 24813514
Clin Gastroenterol Hepatol. 2016 Dec;14(12):1842-1844
pubmed: 27112108
J Allergy Clin Immunol. 2001 Dec;108(6):954-61
pubmed: 11742273
Lancet Gastroenterol Hepatol. 2018 Jul;3(7):477-488
pubmed: 29730081
Lancet Gastroenterol Hepatol. 2018 Apr;3(4):271-280
pubmed: 29533199
Pathol Res Pract. 2018 Jan;214(1):100-104
pubmed: 29103770
Colorectal Dis. 2014 Feb;16(2):123-9
pubmed: 24138295
Gastroenterology. 2018 Jan;154(2):333-345
pubmed: 28757265